BR112016014180A2 - reguladores de nrf2 - Google Patents
reguladores de nrf2Info
- Publication number
- BR112016014180A2 BR112016014180A2 BR112016014180A BR112016014180A BR112016014180A2 BR 112016014180 A2 BR112016014180 A2 BR 112016014180A2 BR 112016014180 A BR112016014180 A BR 112016014180A BR 112016014180 A BR112016014180 A BR 112016014180A BR 112016014180 A2 BR112016014180 A2 BR 112016014180A2
- Authority
- BR
- Brazil
- Prior art keywords
- nrf2 regulators
- nrf2
- regulators
- pharmaceutical compositions
- compositions containing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
- C07D291/08—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
- C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D419/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
- C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D515/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
resumo "reguladores de nrf2" a presente invenção se refere aos análogos de bis arila, composições farmacêuticas contendo os mesmos e seu emprego como reguladores de nrf2.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361917466P | 2013-12-18 | 2013-12-18 | |
US201461980091P | 2014-04-16 | 2014-04-16 | |
PCT/IB2014/067027 WO2015092713A1 (en) | 2013-12-18 | 2014-12-17 | Nrf2 regulators |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112016014180A2 true BR112016014180A2 (pt) | 2017-09-26 |
Family
ID=52355021
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016014180A BR112016014180A2 (pt) | 2013-12-18 | 2014-12-17 | reguladores de nrf2 |
Country Status (19)
Country | Link |
---|---|
US (2) | US10144731B2 (pt) |
EP (1) | EP3083614B1 (pt) |
JP (1) | JP6630671B2 (pt) |
KR (1) | KR102301867B1 (pt) |
CN (1) | CN105829305B (pt) |
AU (2) | AU2014369153B2 (pt) |
BR (1) | BR112016014180A2 (pt) |
CA (1) | CA2934216C (pt) |
CL (1) | CL2016001516A1 (pt) |
CR (1) | CR20160272A (pt) |
DO (1) | DOP2016000145A (pt) |
EA (1) | EA030431B1 (pt) |
ES (1) | ES2784244T3 (pt) |
IL (1) | IL245727B (pt) |
MX (1) | MX370410B (pt) |
PE (1) | PE20160901A1 (pt) |
PH (1) | PH12016501151A1 (pt) |
SG (1) | SG11201604611SA (pt) |
WO (1) | WO2015092713A1 (pt) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107709306A (zh) * | 2015-06-15 | 2018-02-16 | 葛兰素史密斯克莱知识产权发展有限公司 | Nrf2调节剂 |
RS65562B1 (sr) * | 2015-06-15 | 2024-06-28 | Glaxosmithkline Ip Dev Ltd | Nrf2 regulatori |
JP6786527B2 (ja) * | 2015-06-15 | 2020-11-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Nrf2レギュレーター |
US10364256B2 (en) | 2015-10-06 | 2019-07-30 | Glaxosmithkline Intellectual Property Development Limited | Biaryl pyrazoles as NRF2 regulators |
WO2017060855A1 (en) * | 2015-10-06 | 2017-04-13 | Glaxosmithkline Intellectual Property Development Limited | Arylcyclohexyl pyrazoles as nrf2 regulators |
CN105566241B (zh) * | 2016-01-18 | 2018-05-25 | 中国药科大学 | 1-磺酰胺基-4-芳氧基类化合物、制备方法及其医药用途 |
US9845307B2 (en) | 2016-02-03 | 2017-12-19 | Rigel Pharmaceuticals, Inc. | Nrf2 activating compounds and uses thereof |
WO2018104766A1 (en) * | 2016-12-06 | 2018-06-14 | Glaxosmithkline Intellectual Property Development Limited | 3-(2,3-dihydro-1h-inden-5-yl)propanoic acid derivatives and their use as nrf2 regulators |
WO2018109642A1 (en) * | 2016-12-12 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | N-aryl pyrazoles as nrf2 regulators |
JP2020500919A (ja) * | 2016-12-12 | 2020-01-16 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Nrf2レギュレーターとしての3−カルボン酸ピロール |
ES2848699T3 (es) * | 2016-12-14 | 2021-08-11 | Glaxosmithkline Ip Dev Ltd | Compuestos de 3-oxo-1,4-diazepinilo como activadores de NRF2 |
US11117905B2 (en) | 2016-12-14 | 2021-09-14 | Glaxosmithkline Intellectual Property Development Limited | Bisaryl heterocycles as NRF2 activators |
WO2018109647A1 (en) | 2016-12-14 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | Bisaryl amides as nrf2 regulators |
EP3555082B1 (en) * | 2016-12-15 | 2022-01-26 | GlaxoSmithKline Intellectual Property Development Limited | Ether linked triazoles as nrf2 regulators |
EP3555104B1 (en) | 2016-12-15 | 2021-11-24 | GlaxoSmithKline Intellectual Property Development Limited | Nrf2 compounds |
WO2018145109A1 (en) | 2017-02-06 | 2018-08-09 | Massachusetts Institute Of Technology | Methods and products related to glutaminase inhibitors |
JP2020097526A (ja) * | 2017-03-28 | 2020-06-25 | 武田薬品工業株式会社 | 複素環化合物 |
WO2019116231A1 (en) | 2017-12-11 | 2019-06-20 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome |
US20210177861A1 (en) * | 2017-12-11 | 2021-06-17 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome |
EP3796906A1 (en) * | 2018-05-23 | 2021-03-31 | GlaxoSmithKline Intellectual Property Management Limited | Indanes as nrf2 activators |
WO2020018788A1 (en) * | 2018-07-20 | 2020-01-23 | Dana-Farber Cancer Institute, Inc. | Degraders that target proteins via keap1 |
CN112930347B (zh) * | 2018-08-20 | 2024-07-23 | 詹森药业有限公司 | KEAP1-Nrf2蛋白-蛋白相互作用的抑制剂 |
BR112021010704A2 (pt) * | 2018-12-05 | 2021-08-24 | Scohia Pharma, Inc. | Composto macrocíclico e uso do mesmo |
MA54939A (fr) | 2019-02-15 | 2021-12-22 | Glaxosmithkline Ip Dev Ltd | Hydroxypyridoxazépines utilisées en tant qu'activateurs de nrf2 |
WO2020210229A1 (en) * | 2019-04-08 | 2020-10-15 | Dana-Farber Cancer Institute, Inc. | Degraders of kelch-like ech-associated protein 1 (keap1) |
EP3978073A4 (en) | 2019-05-31 | 2023-07-12 | UBE Corporation | BENZOTRIAZOLE DERIVATIVE |
JPWO2021002473A1 (pt) | 2019-07-03 | 2021-01-07 | ||
KR20220148851A (ko) | 2020-02-28 | 2022-11-07 | 르 라보레또레 쎄르비에르 | 신규한 매크로사이클릭 화합물, 이들의 제조 방법 및 이들을 함유하는 약학적 조성물 |
AU2021411868A1 (en) | 2020-12-28 | 2023-07-20 | Senju Pharmaceutical Co., Ltd. | Nrf2-activating compound |
WO2023210741A1 (ja) * | 2022-04-28 | 2023-11-02 | 第一三共株式会社 | ベンゾトリアゾール化合物 |
CN117603075B (zh) * | 2024-01-18 | 2024-04-12 | 深圳创元生物医药科技有限公司 | 一种碳13标记的3-羧酸苯丙氨酸的制备方法 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL99537A (en) | 1990-09-27 | 1995-11-27 | Merck & Co Inc | Fibrinogen receptor antagonists and pharmaceutical preparations containing them |
US5217994A (en) | 1991-08-09 | 1993-06-08 | Merck & Co., Inc. | Method of inhibiting osteoclast-mediated bone resorption by administration of aminoalkyl-substituted phenyl derivatives |
US5534654A (en) | 1991-12-10 | 1996-07-09 | Shionogi & Co., Ltd. | Aromatic-sulfonamide-type hydroxamic acid derivative |
ATE227567T1 (de) | 1994-05-27 | 2002-11-15 | Merck & Co Inc | Präparate zur hemmung der durch osteoklasten vermittelten knochenresorption |
TWI262185B (en) | 1999-10-01 | 2006-09-21 | Eisai Co Ltd | Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives |
TWI284639B (en) | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
CA2435829A1 (en) | 2001-01-25 | 2002-08-01 | Guilford Pharmaceuticals Inc. | Trisubstituted carbocyclic cyclophilin binding compounds and their use |
JPWO2002080899A1 (ja) | 2001-03-30 | 2005-01-06 | エーザイ株式会社 | 消化器疾患治療剤 |
TWI311133B (en) | 2001-04-20 | 2009-06-21 | Eisai R&D Man Co Ltd | Carboxylic acid derivativeand the salt thereof |
TWI331526B (en) | 2001-09-21 | 2010-10-11 | Bristol Myers Squibb Pharma Co | Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
CN104744461A (zh) | 2001-09-21 | 2015-07-01 | 百时美施贵宝公司 | 含有内酰胺的化合物及其衍生物作为Xa因子的抑制剂 |
US20040157919A1 (en) | 2002-01-25 | 2004-08-12 | Yong-Qian Wu | Trisubstituted carbocyclic cyclophilin binding compounds and their use |
AU2003281039A1 (en) | 2002-07-10 | 2004-02-02 | Sumitomo Pharmaceuticals Co., Ltd. | Imidazole derivative |
WO2006044133A1 (en) | 2004-09-24 | 2006-04-27 | Axys Pharmaceuticals, Inc. | Active ketone inhibitors of tryptase |
JP5000490B2 (ja) | 2005-04-28 | 2012-08-15 | 武田薬品工業株式会社 | チエノピリミドン化合物 |
ES2436028T3 (es) | 2006-06-23 | 2013-12-26 | Radius Health, Inc. | Tratamiento de síntomas vasomotores con moduladores selectivos de receptores de estrógeno |
EP2240434A1 (en) * | 2008-01-07 | 2010-10-20 | Ligand Pharmaceuticals Inc. | 2-phenyl phenoxyacetic acids useful for treating inflammatory disorders |
MX2011000051A (es) | 2008-07-07 | 2011-07-28 | Fasgen Inc | Nuevos compuestos, composiciones farmaceuticas que contienen los mismos, metodos para usar los mismos, y metodos para preparar los mismos. |
WO2010018112A2 (en) * | 2008-08-15 | 2010-02-18 | F. Hoffmann-La Roche Ag | Monoaryl aminotetralines |
WO2011094890A1 (en) | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
CN102762101B (zh) * | 2010-02-18 | 2014-09-17 | 高点制药有限责任公司 | 取代的稠合咪唑衍生物、药物组合物及其使用方法 |
US20130310379A1 (en) | 2010-11-19 | 2013-11-21 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
US20140256767A1 (en) * | 2011-10-31 | 2014-09-11 | The Broad Institute, Inc. | Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators |
WO2013122028A1 (ja) * | 2012-02-13 | 2013-08-22 | 武田薬品工業株式会社 | 芳香環化合物 |
WO2013155528A2 (en) | 2012-04-13 | 2013-10-17 | Fasgen, Inc. | Methods for reducing brain inflammation, increasing insulin sensitivity, and reducing ceramide levels |
-
2014
- 2014-12-17 CN CN201480069879.3A patent/CN105829305B/zh active Active
- 2014-12-17 US US15/105,306 patent/US10144731B2/en active Active
- 2014-12-17 PE PE2016000789A patent/PE20160901A1/es unknown
- 2014-12-17 WO PCT/IB2014/067027 patent/WO2015092713A1/en active Application Filing
- 2014-12-17 JP JP2016541128A patent/JP6630671B2/ja active Active
- 2014-12-17 CA CA2934216A patent/CA2934216C/en active Active
- 2014-12-17 MX MX2016008134A patent/MX370410B/es active IP Right Grant
- 2014-12-17 BR BR112016014180A patent/BR112016014180A2/pt active Search and Examination
- 2014-12-17 ES ES14827868T patent/ES2784244T3/es active Active
- 2014-12-17 KR KR1020167018852A patent/KR102301867B1/ko active IP Right Grant
- 2014-12-17 SG SG11201604611SA patent/SG11201604611SA/en unknown
- 2014-12-17 CR CR20160272A patent/CR20160272A/es unknown
- 2014-12-17 EA EA201691259A patent/EA030431B1/ru not_active IP Right Cessation
- 2014-12-17 AU AU2014369153A patent/AU2014369153B2/en active Active
- 2014-12-17 EP EP14827868.2A patent/EP3083614B1/en active Active
-
2016
- 2016-05-19 IL IL24572716A patent/IL245727B/en active IP Right Grant
- 2016-06-14 PH PH12016501151A patent/PH12016501151A1/en unknown
- 2016-06-15 CL CL2016001516A patent/CL2016001516A1/es unknown
- 2016-06-17 DO DO2016000145A patent/DOP2016000145A/es unknown
-
2017
- 2017-12-20 AU AU2017279668A patent/AU2017279668B2/en active Active
-
2018
- 2018-09-06 US US16/122,968 patent/US20190002454A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20160098392A (ko) | 2016-08-18 |
IL245727A0 (en) | 2016-08-02 |
EP3083614A1 (en) | 2016-10-26 |
PH12016501151A1 (en) | 2016-07-25 |
US20160318917A1 (en) | 2016-11-03 |
CR20160272A (es) | 2016-08-16 |
KR102301867B1 (ko) | 2021-09-15 |
JP6630671B2 (ja) | 2020-01-15 |
AU2014369153B2 (en) | 2017-09-21 |
JP2017503786A (ja) | 2017-02-02 |
EA201691259A1 (ru) | 2016-11-30 |
AU2014369153A1 (en) | 2016-05-26 |
SG11201604611SA (en) | 2016-07-28 |
US20190002454A1 (en) | 2019-01-03 |
CA2934216C (en) | 2021-03-16 |
WO2015092713A1 (en) | 2015-06-25 |
EA030431B1 (ru) | 2018-08-31 |
CN105829305B (zh) | 2018-11-30 |
CA2934216A1 (en) | 2015-06-25 |
CL2016001516A1 (es) | 2016-12-16 |
MX370410B (es) | 2019-12-11 |
PE20160901A1 (es) | 2016-08-27 |
US10144731B2 (en) | 2018-12-04 |
AU2017279668A1 (en) | 2018-01-18 |
DOP2016000145A (es) | 2016-07-31 |
IL245727B (en) | 2019-10-31 |
ES2784244T3 (es) | 2020-09-23 |
MX2016008134A (es) | 2016-08-12 |
AU2017279668B2 (en) | 2019-04-04 |
CN105829305A (zh) | 2016-08-03 |
EP3083614B1 (en) | 2020-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016014180A2 (pt) | reguladores de nrf2 | |
DOP2017000298A (es) | Reguladores de nrf2 | |
CR20210079A (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
CR20150370A (es) | Compuestos antivirales | |
UY36489A (es) | Uso de compuestos de picolinamida con actividad fuingicida | |
UY35469A (es) | Moduladores de p2x7 | |
UY34820A (es) | Compuestos tipo pirrolo-pirrolidinona | |
BR112017007123A2 (pt) | derivados de tetrahidroisoquinolina | |
BR112017008659A2 (pt) | ?métodos e compostos de agonista de gip? | |
BR112016006874A2 (pt) | uso de picolinamidas macrocíclicas como fungicidas | |
BR112017013767A2 (pt) | uso de picolinamidas como fungicidas | |
BR112016006366A2 (pt) | uso de picolinamidas macrocíclicas como fungicidas | |
UY34472A (es) | Derivados modificados de 4-fenil-piridina | |
UY34550A (es) | Bencilpirazoles sustituidos | |
CU20140081A7 (es) | Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
CR20150277A (es) | Piridina-2-amidas utiles como agonistas cb2 | |
CU20140095A7 (es) | Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
CR20150271A (es) | Peptidos como agonistas de oxitocina | |
CR20130671A (es) | Antagonistas de trpv4 | |
CR20150440A (es) | Nuevos derivados de piridina | |
UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
CR20150511A (es) | Nuevos derivados de purina | |
CR20150084A (es) | 2-oxo-2,3-dihidro-indoles | |
CR20160448A (es) | Nuevos derivados de piridina | |
UY35997A (es) | Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 417/10 Ipc: C07D 417/10 (2006.01), A61P 11/00 (2006.01), A61P |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B11D | Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time |